ANGPT1 and endothelial dysfunction: Moreover, a higher angiopoietin-2/angiopoietin-1 balance, indicating endothelial activation, at pre-LD was identified in patients subsequently developing ICANS, suggesting endothelial dysfunction prior to CAR T-cell therapy could influence the occurrence of toxicity [9].